• Global frequency, diagnosis, and treatment of hereditary angioedema with normal C1 inhibitor.

  Magerl M, Riedl MA, Arruda LK, Bauer A, Berardi A, Bernstein JA, Bouillet L, Buckland M, Buttgereit T, Cohn DM, Craig T, Criado RF, Du-Thanh A, Fain O, Gonçalo M, Greve J, Grumach AS, Guilarte M, Katelaris C, Kinaciyan T, Latysheva EA, Lleonart R, Llosa OC, Mansour E, Grivcheva-Panovska V, Parisi C, Rosario Filho NA, Santos AS, Staubach P, Valerieva A, Rodrigues Valle SO, Danese S, Ulloa J, Audhya PK, Maurer M.J Allergy Clin Immunol Glob. 2025 Feb 27;4(3):100446. doi: 10.1016/j.jacig.2025.100446. 

• The Chronic Angioedema Registry (CARE): Rationale, Methods and Implementation.

  Buttgereit, T; Aulenbacher, F; Gutsche, A; Kolkhir, P; Weller, K; Vera, Ayala, C; Magerl, M; Farkas, H; Grumach, AS; Aygören-Pürsün, E; Bara, N; Ben-Shoshan, M; Bernstein, J; Betschel, S; Bouillet, L; Caballero, T; Cancian, M; Castaldo, AJ; Cimbollek, S; Cohn, DM; Craig, T; Fomina, D; Gelincik, A; Grivcheva-Panovska, V; Jindal, A; Katelaris, C; Kessel, A; Kinaciyan, T; Longhurst, HJ; Martinez-Saguer, I; Riedl, M; Schöffl, C; Staubach, P; Zanichelli, A; Zhi, Y; Balle, Boysen, H; Fok, JS; Li, PH; Hakl, R; Hide, M; Peter, J; Maurer, M Clin Exp Allergy. 2024; Doi: 10.1111/cea.14527

• Meta-analysis of ACE inhibitor-induced angioedema identifies novel risk locus.

  Mathey, CM; Maj, C; Eriksson, N; Krebs, K; Westmeier, J; David, FS; Koromina, M; Scheer, AB; Szabo, N; Wedi, B; Wieczorek, D; Amann, PM; Löffler, H; Koch, L; Schöffl, C; Dickel, H; Ganjuur, N; Hornung, T; Buhl, T; Greve, J; Wurpts, G; Aygören-Pürsün, E; Steffens, M; Herms, S; Heilmann-Heimbach, S; Hoffmann, P; Schmidt, B; Mavarani, L; Andresen, T; Sørensen, SB; Andersen, V; Vogel, U; Landén, M; Bulik, CM; Bygum, A; Magnusson, PKE; von, Buchwald, C; Hallberg, P; Rye, Ostrowski, S; Sørensen, E; Pedersen, OB; Ullum, H; Erikstrup, C; Bundgaard, H; Milani, L; Rasmussen, ER; Wadelius, M; Ghouse, J; Sachs, B; Nöthen, MM; Forstner, AJ, , Estonian, Biobank, Research, Team;DBDS, Genomic, Consortium. J Allergy Clin Immunol. 2024; Doi: 10.1016/j.jaci.2023.11.921  

• Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus.

  Reshef A, Buttgereit T, Betschel SD, Caballero T, Farkas H, Grumach AS, Hide M, Jindal AK, Longhurst H, Peter J, Riedl MA, Zhi Y, Aberer W, Abuzakouk M, Al Farsi T, Al Sukaiti N, Al-Ahmad M, Altrichter S, Aygören-Pürsün E, Baeza ML, Bara NA, Bauer A, Bernstein JA, Boccon-Gibod I, Bonnekoh H, Bouillet L, Brzoza Z, Bygum A, Calderon O, de Albuquerque Campos R, Campos Romero FH, Cancian M, Chong-Neto HJ, Christoff G, Cimbollek S, Cohn DM, Craig T, Danilycheva I, Darlenski R, Du-Thanh A, Ensina LF, Fomina D, Fonacier L, Fukunaga A, Gelincik A, Giavina-Bianchi P, Godse K, Gompels M, Goncalo M, Gotua M, Guidos-Fogelbach G, Guilarte M, Kasperska-Zajac A, Katelaris CH, Kinaciyan T, Kolkhir P, Kulthanan K, Kurowski M, Latysheva E, Lauerma A, Launay D, Lleonart R, Lumry W, Malbran A, Ali RM, Nasr I, Nieto-Martinez S, Parisi C, Pawankar R, Piñero-Saavedra M, Popov TA, Porebski G, Prieto Garcia A, Pyatilova P, Rudenko M, Sekerel BE, Serpa FS, Sheikh F, Siebenhaar F, Soria A, Staevska M, Staubach P, Stobiecki M, Thomsen SF, Triggiani M, Valerieva A, Valle S, Van Dinh N, Vera Ayala CE, Zalewska-Janowska A, Zanichelli A, Magerl M, Maurer M. J Allergy Clin Immunol. 2024; 154: 398-411

• A core outcome set for efficacy of acute treatment of hereditary angioedema.

  Petersen RS, Fijen LM, Apfelbacher C, Magerl M, Weller K, Aberer W, Adatia A, Audhya P, Bara NA, Betschel S, Boccon-Gibod I, Bouillet L, Brodszki N, Busse PJ, Buttgereit T, Bygum A, Cancian M, Craig T, Csuka D, Farkas H, Fomina D, Gil-Serrano J, Gompels M, Fogelbach GG, Guilarte M, Hide M, Kiani-Alikhan S, Kinaciyan T, Lenten A, Lleonart R, Longhurst H, Lumry WR, Malbran A, Malinauskiene L, Matta Campos JJ, Mendivil J, Nieto-Martinez SA, Peter JG, Porebski G, Reshef A, Riedl M, Valerieva A, Waserman S, Maurer M, Cohn DM. J Allergy Clin Immunol Pract. 2024; 12: 1614-1621

• Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial.

  Kiani-Alikhan S, Gower G, Craig T, Wedner HJ, Kinaciyan T, Aygören-Pürsün E, Banerji A, Bernstein JA, Anderson J, Collis P, Johnston DT, Desai B, Tomita D, Gagnon R, Tachdjian R, Soteres DF, Farkas H, Caballero T, McNeil D, Jacobs J, and Lumry WR, on behalf of the APeX-2 investigators: J Allergy Clin Immunol Pract. 2024;12: 733-43

• A Retrospective Analysis of Long-Term Prophylaxis with Berotralstat in Patients with Hereditary Angioedema and Acquired C1-Inhibitor Deficiency-Real-World Data. 

  Johnson F, Stenzl A, Hofauer B, Heppt H, Ebert EV, Wollenberg B, Lochbaum R,     Hahn J, Greve J, Trainotti S. Clin Rev Allergy Immunol. 2023 Dec;65(3):354-364. doi: 10.1007/s12016-023-08972-2. 

• Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)-A Bicenter Retrospective Study on Diagnosis, Course, and Therapy.

  Trainotti S, Johnson F, Hahn J, Hofauer B, Greve J, Wollenberg B, Hoffmann TK, Lochbaum R.J Allergy Clin Immunol Pract. 2023 Dec;11(12):3772-3779. doi: 10.1016/j.jaip.2023.09.003

• Hereditary angioedema due to C1-inhibitor deficiency, a national disease management programme. Hereditäres Angioödem durch C1-Inhibitor-Mangel, eine nationale Versorgungsleitlinie

  Aberer W, Altrichter S, Cerpes U, Hawranek T, Schöffl C, Kinaciyan T. Wien Klin Wochenschr. 2023;135(Suppl 8):785-98 https://ncbi.nlm.nih.gov/pmc/articles/PMC10709250/pdf/508_2023_Article_2298.pd
  Kurzfassung: Die aktuelle österreichische Leitlinie zum hereditären Angioödem (HAE) baut auf bestehenden internationalen Leitlinien auf und berücksichtigt dabei die nationalen, lokalen Gegebenheiten. Sie legt großen Wert auf einen individualisierten, patientenzentrierten Ansatz, Fortschritte in der Therapie und die Förderung der Heimbehandlung. Zudem wird auf die Verordnung von Zweitlinientherapien wie Androgenen und Antifibrinolytika dezidiert verzichtet, da diese langfristig schlecht verträglich sind, bzw. nicht ausreichend wirksam, und deshalb nicht mehr empfohlen werden. Ein zentrales Ziel der Leitlinie ist die frühzeitige korrekte Diagnosestellung, da diese in Österreich bislang oft um mehr als 20 Jahre nach Symptombeginn erfolgt. Die Diagnose ist einfach, sie ergibt sich aus der passenden Anamnese und wird beim klassischen HAE durch biochemische Tests bestätigt. Die Therapie konzentriert sich auf die Behandlung akuter Schwellungsattacken sowie auf die Langzeitprophylaxe. Hierfür existieren unterschiedliche Therapien, und neu vielversprechende Therapieansätze, die sich aktuell in klinischen Studien befinden, bieten Hoffnung auf weiter verbesserte Behandlungsergebnisse. 

• An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.

  Aygören-Pürsün E, Zanichelli A, Cohn DM, Cancian M, Hakl R, Kinaciyan T, Magerl M, Martinez-Saguer I, Stobiecki M, Farkas H, Kiani-Alikhan S, Grivcheva-Panovska V, Bernstein JA, Li HH, Longhurst HJ, Audhya PK, Smith MD, Yea CM, Maetzel A, Lee DK, Feener EP, Gower R, Lumry WR, Banerji A, Riedl MA, Maurer M. The Lancet. 2023 Feb 11;401(10375):458-469. 

• The international WAO/EAACI guideline for the management of hereditary angioedema - the 2021 revision and update. In Japanese

  Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygören-Pürsün E, Banerji A, Bara NA, Boccon-Gibod I, Bork K, Bouillet L, Boysen HB, Brodszki N, Busse PJ, Bygum A, Caballero T, Cancian M, Castaldo A, Cohn DM, Csuka D, Farkas H, Gompels M, Gower R, Grumach AS, Guidos-Fogelbach G, Hide M, Kang HR, Kaplan AP, Katelaris C, Kiani-Alikhan S, Lei WT, Lockey R, Longhurst H, Lumry WR, MacGinnitie A, Malbran A, Saguer IM, Matta JJ, Nast A, Nguyen D, Nieto-Martinez SA, Pawankar R, Peter J, Porebski G, Prior N, Reshef A, Riedl M, Ritchie B, Sheikh FR, Smith WB, Spaeth PJ, Stobiecki M, Toubi E, Varga LA, Weller K, Zanichelli A, Zhi Y, Zuraw B, Craig T.
  Arerugi. 72(3):237-272, 2023

• Expert consensus on the prophylactic treatment of hereditaryangioedema.

  Greve J, Kinaciyan T, Maurer M, Dillenburger B, Recke A, Schöffl C. Allergo J Int 2022; 31: 233-242

• Expertenkonsensus zur Prophylaxebehandlung des hereditären Angioödems.

  Greve J, Kinaciyan T, Maurer M, Dillenburger B, Recke A, Schöffl C. Allergo J Int 2022, 7: 22-34

• Molecular Genetic Screening in Patients with ACE Inhibitor/Angiotensin Receptor Blocker-Induced Angioedema to Explore the Role of Hereditary Angioedema Genes.

  Mathey, CM; Maj, C; Scheer, AB; Fazaal, J; Wedi, B; Wieczorek, D; Amann, PM; Löffler, H; Koch, L; Schöffl, C; Dickel, H; Ganjuur, N; Hornung, T; Forkel, S; Greve, J; Wurpts, G; Hallberg, P; Bygum, A; Von, Buchwald, C; Karawajczyk, M; Steffens, M; Stingl, J; Hoffmann, P; Heilmann-Heimbach, S; Mangold, E; Ludwig, KU; Rasmussen, ER; Wadelius, M; Sachs, B; Nöthen, MM; Forstner, AJ. Front Genet. 2022; 13: 914376 Doi: 10.3389/fgene.2022.914376

• The Icatibant Outcome Survey: 10 years of experience with icatibant for patients with hereditary angioedema

  Maurer M, Aberer W, Caballero T, Bouillet L, Grumach AS, Botha J, Andresen I, Longhurst HJ; IOS Study Group. Clin Exp Allergy. 2022; 52: 1048-1058

• The international WAO/EAACI guideline for the management of hereditary angioedema - the 2021 revision and update.

  Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygören-Pürsün E, Banerji A, Bara NA, Boccon-Gibod I, Bork K, Bouillet L, Balle Boysen H, Brodszki N, Busse PJ, Bygum A, Caballero T, Cancian M, Castaldo A, Cohn DM, Csuka D, Farkas H, Gompels M, Gower R, Grumach AS, Guidos-Fogelbach G, Hide M, Kang HR, Kaplan AP, Katelaris C, Kiani-Alikhan S, Lei WT, Lockey R, Longhurst H, Lumry WR, MacGinnitie A, Malbran A, Martinez Saguer I, Matta JJ, Nast A, Nguyen D, Nieto-Martinez SA, Pawankar R, Peter J, Porebski G, Prior N, Reshef A, Riedl M, Ritchie B, Rafique Sheikh F, Smith WR, Spaeth PJ, Stobiecki M, Toubi E, Agnes Varga L, Weller K, Zanichelli A, Zhi Y, Zuraw B, Craig T. Allergy 2022, 77:1961-1990

• Variability of disease activity in patients with hereditary angioedema type 1/2: longitudinal data from the Icatibant Outcome Survey.

  Maurer M, Caballero T, Aberer W, Zanichelli A, Bouillet L, Bygum A, Grumach AS, Botha J, Andresen I, Longhurst HJ; IOS Study Group. J Eur Acad Dermatol Venereol. 2021; 35: 2421-2430

• The crux of C1-INH testing in everyday lab work.

  Schöffl C, Haas A, Herrmann M, Aberer W. J Immunol Methods. 2021 Oct;497:113109. doi: 10.101

• Hereditary angioedema: An orphan but an original disease?

  Aberer W. J Allergy Clin Immunol. 2021; 148: 994-995

• Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema.

  Farkas H, Reshef A, Caballero T, López MCO, Kessel A, Vardi M, Hao J, Aberer W. Pediatric Allergy Immunology. 2021, 32: 1392-1396

• Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study.

  Farkas H, Stobiecki M, Peter J. Kinaciyan T, Maurer M. Aygören‐Pürsün E, Kiani‐Alikhan S, Wu A, Reshef A, Bygum A, Fain O, Hagin D, Huissoon A, Jeseňák M, Lindsay K, Grivcheva Panovska V, Steiner UC, Zubrinich C, Best JM, Cornpropst M, Dix D, Dobo SM, Iocca HA, Desai B, Murray SC, Nagy E, Sheridan WP. Clin Transl Allergy. 2021 Jun;11(4):e12035. doi: 10.1002/clt2.12035.

• Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema.

  Farkas H, Reshef A, Caballero T, López MCO, Kessel A, Vardi M, Hao J, Aberer W. Pediatric Allergy Immunology. 2021, 32: 1392-1396

• Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial.

  Zuraw B, Lumry WR, Johnston DT, Aygören-Pürsün E, Banerji A, Bernstein JA, Christiansen SC, Jacobs JS, Sitz KV, Gower RG, Gagnon R, Wedner HJ, Kinaciyan T, Hakl R, Hanzlíková J, Anderson JT, McNeil DL, Fritz SB, Yang WH, Tachdjian R, Busse PJ, Craig TJ, Li HH, Farkas H, Best JM, Clemons D, Cornpropst M, Dobo SM, Iocca HA, Kargl D, Nagy E, Murray SC, Collis P, Sheridan WP, Maurer M, Riedl MA. J Allergy Clin Immunol. 2020 Jul;148(1):164-172.e9. 

• Development of the Angioedema Control Test-A patient-reported outcome measure that assesses disease control in patients with recurrent angioedema.

  Weller K, Donoso T, Magerl M, Aygören-Pürsün E, Staubach P, Martinez-Saguer I, Hawro T, Altrichter S, Krause K, Siebenhaar F, Metz M, Zuberbier T, Freier D, Maurer M. Allergy. 2020 May;75(5):1165-1177.

• Validation of the Angioedema Control Test (AECT)-A Patient-Reported Outcome Instrument for Assessing Angioedema Control.

  Weller K, Donoso T, Magerl M, Aygören-Pürsün E, Staubach P, Martinez-Saguer I, Hawro T, Altrichter S, Krause K, Siebenhaar F, Metz M, Zuberbier T, Freier D, Maurer M.J Allergy Clin Immunol Pract. 2020 Jun;8(6):2050-2057.e4. doi: 10.1016/j.jaip.2020.02.038. Epub 2020 Mar 12.

• Definition, aims, and implementation of GA²LEN/HAEi Angioedema Centers of Rference and Excellence.

  Maurer M, Aberer W, Agondi R, Al-Ahmad M, Al-Nesf M, Ansotgui I, Arnaout R, Arruda LK, Asero R, Aygören-Pürsün E, Banerji A, Bauer A, Ben-Shoshan M, Berardi A, Bernstein J, Betschel S, Bindslev-Jensen C, Bizjak M, Boccon-Gibod I, Bork K, Bouillet L, Boysen HB, Brodszki N, Broesby-Olsen S, Busse P, Buttgereit T, Bygum A, Caballero T, Campos RA, Cancian M, Cherrez-Ojeda I, Cohn DM, Costa C, Craig T, Criado PR, Criado R, Csuka D, Dissemond J, Du-Thanh A, Ensina LF, Ertaş R, Fabiani JE, Fantini C, Farkas H, Ferrucci SM, Figueras-Nart I, Fili, NL, Fomina D, Fukunaga A, Gelincik A, Giménez-Arnau A, Godse K, Gompels M, Gonçalo M, Gotua M, Gower R, Grumach AS, Guidos-Fogelbach G, Hide M, Ilina N, Inomata N, Jakob T, Josviack DO, Kang H-R, Kaplan A, Kasperska-Zając A, Katelaris C, Kessel A, Kleinheinz A, Kocatürk E, Košnik M, Krasowska D, Kulthanan K, Kumaran MS, Larco Sousa JI, Longhurst HI, Lumry W, MacGinnitie A, Magel M, Makris MP, Malbrán A, Marsland A, Martinez-Saguer I, Medina IV, Meshkova R, Metz M, Nasr I, Nicolay J, Nishigori C, Ohsawa I, Özyurt K, Papadopoulos NG, Parisi CA S, Peter JG, Pfützner W, Popov T, Prior N, Ramon GD, Reich A, Reshef A, Riedl MA, Ritchie B, Röckmann-Helmbach H, Rudenko M, Salman A, Sanchez-Borges M, Schmid-Grendelmeier P, Serpa FS, Serra-Baldrich E, Sheikh FR, Smith W, Soria A, Staubach P, Steiner UC, Stobieck, M, Sussman G, Tagka A, Thomsen SF, Treudler R, Valle S, van Doorn M, Varga L, Vázquez DO, Wagner N, Wang L, Weber-Chrysochoou C, Ye Y-M, Zalewska-Janowska A, Zanichelli A, Zhao Z, Zhi Y, Zuberbier T, Zwiener RD, and Castaldo A: Allergy 2020: 75; 2115-2123

• Hereditary angioedema in children and adolescents - A consensus update on therapeutic strategies for German-speaking countries.

  Wahn V, Aberer W, Aygören-Pürsün E, Bork K, Eberl W, Faßhauer M, Krüger R, Magerl M, Martinez-Saguer I, Späth P, Staubach-Renz P, Weber-Chrysochoou C. Pediatr Allergy Immunol. 2020; 31: 974-989

• Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey.

  Bygum A, Caballero T, Grumach AS, Longhurst HJ, Bouillet L, Aberer W, Zanichelli A, Botha J, Andresen I, Maurer M, for the IOS Study Group. Clinical Translational Allergy 9, 37-37, 2019.

• Pediatricians diagnosed few patients with childhood-presented hereditary angioedema: Icatibant Outcome Survey findings. Icatibant Outcome Survey investigators.

  Grumach AS, Longhurst HJ, Aberer W, Bouillet L, Caballero T, Bygum A, Zanichelli A, Botha J, Andresen I, Maurer M; Journal Allergy Clinical Immunology Practice 7,1078-1080, 2019

• Hereditäres Angioödem in Österreich: Prävalenz und regionale Besonder-  heiten.

  Schöffl C, Wiednig M, Koch L, Blagojevic D, Duschet P, Hawranek T, Kinaciyan T,Öllinger A, Aberer W. Journal der Deutschen Dermatologischen Gesellschaft 17, 416-424, 2019 https://pubmed.ncbi.nlm.nih.gov/30883006/(englischeVersion) https://pubmed.ncbi.nlm.nih.gov/30958937/ (deutsche Version)
  Kurzfassung: In einer ersten nationalen Umfrage wurden aktuelle Daten zur Prävalenz und zu den klinischen Merkmalen österreichischer Patienten mit hereditärem Angioödem (HAE) erhoben. Insgesamt wurden 137 Patienten identifiziert, was einer Prävalenz von 1 : 64.396 entspricht. Das mediane Alter beim Auftreten der ersten Symptome lag bei 6,5 Jahren, während die korrekte Diagnose erst im Durchschnitt im Alter von 21 Jahren gestellt wurde. Für neu diagnostizierte Patienten ohne familiäre HAE-Vorgeschichte betrug die mediane Diagnoseverzögerung 15 Jahre. Trotz vieler Fortschritte warten Patienten, die nach 1980 geboren wurden, immer noch im Median 6,5 Jahre auf die korrekte Diagnose. Dies zeigt den dringenden Bedarf an einem erhöhten Bewusstsein für HAE unter Fachärzten und Allgemeinmedizinern.

• Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey.

  Zanichelli A, Magerl M, Longhurst HJ, Aberer W, Caballero T, Bouillet L, Bygum A, Grumach AS, Botha J, Andresen I, Maurer M; IOS Study Group. Clinical Translational Allergy 2018 Oct 12;8:42. doi: 10.1186/s13601-018-0229-4. eCollection 2018

• Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema.

  Aygören-Pürsün E, Bygum A, Grivcheva-Panovska V, Magerl M, Graff J,   Steiner cUC, Fain O, Huissoon A, Kinaciyan T, Farkas H, Lleonart R, Longhurst HJ, Rae W, Triggiani M, Aberer W, Cancian M, Zanichelli A, Smith WB, Baeza ML, Du-Thanh A, Gompels M, Gonzalez-Quevedo T, Greve J, Guilarte M, Katelaris C, Dobo S, Cornpropst M, Clemons D, Fang L, Collis P, Sheridan W, Maurer M, Cicardi M. New England Journal Medicine 379, 352-362, 2018

• Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study.

  Caballero T, Zanichelli A, Aberer W, Maurer M, Longhurst HJ, Bouillet L, Andresen I, and the IOS Study Group. Clinical Translational Allergy 2018, 8, 11. doi: 10.1186/s13601-018-0195-x. eCollection 2018

• Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey.

  Aberer W, Maurer M, Bouillet L, Zanichelli A, Caballero T, Longhurst HJ, Perrin A, Andresen I; IOS Study Group. Allergy Asthma Clinical Immunology Jul 5, 13:31, 2017

• Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.

  Farkas H, Reshef A, Aberer W, Caballero T, McCarthy L, Hao J, Nothaft W, Schranz J, Bernstein JA, Li HH. Journal Allergy Clin Immunol Practice 5, 1671-1678, 2017

• The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries.

  Caballero T, Aberer W, Longhurst HJ, Maurer M, Zanichelli A, Perrin A, Bouillet L, Andresen I; IOS Study Group. Journal European Academy Dermatology Venereology 31, 1214-1222, 2017

• Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice.

  Zanichelli A, Maurer M, Aberer W, Caballero T, Longhurst H, Bouillet L, Fabien V, Andresen I; IOS Study Group. Allergy 72, 994-998, 2017

• Comparing acquired angioedema with hereditary angioedema (type I/II): Findings from the Icatibant Outcome Survey.

  Longhurst HJ, Zanichelli A, Caballero T, Bouillet L, Aberer W, Maurer M, Fain O, Fabien V, Andresen I; for the IOS Study Group. Clinical Experimental Immunology 188,148-153, 2017

• Triggers and Prodromal Symptoms of Angioedema Attacks in Patients With Hereditary Angioedema.

  Caballero T, Maurer M, Longhurst HJ, Aberer W, Bouillet L, Fabien V; IOS Study Group Journal of Investigative Allergology Clinical Immunology 26, 383-386, 2016

• Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting.

  Zanichelli A, Longhurst HJ, Maurer M, Bouillet L, Aberer W, Fabien V, Andresen I, Caballero T; IOS Study Group. Annals Allergy Asthma Immunology 117, 394-398, 2016

• Psychometric Field Study of Hereditary Angioedema Quality of Life Questionnaire for Adults: HAE-QoL.

  Prior N, Remor E, Pérez-Fernández E, Caminoa M, Gómez-Traseira C, Gayá F, Aabom A, Aberer W, Betschel S, Boccon-Gibod I, Bouillet L, Bygum A, Csuka D, Farkas H, Gomide M, Grumach A, Leibovich I, Malbran A, Moldovan D, Mihaly E, Obtulowicz K, Perpén C, Peveling-Oberhag A, Porebski G, Chavannes CR, Reshef A, Staubach P, Wiednig M, Caballero T. Journal Allergy Clinical Immunology Practice 4, 464-473, 2016

• The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks.

  Longhurst HJ, Aberer W, Bouillet L, Caballero T, Maurer M, Fabien V, Zanichelli A; IOS Study Group. European Journal Emergency Medicine 23, 224-227, 2016

• Analysis of characteristics associated with reinjection of icatibant: Results from the icatibant outcome survey.

  Longhurst HJ, Aberer W, Bouillet L, Caballero T, Fabien V, Zanichelli A, Maurer M; IOS Investigators. Allergy Asthma Proceedings 36, 399-406, 2015

• Treatment of HAE attacks in the Icatibant Outcome Survey: an analysis of icatibant self-administration versus administration by health care professionals.

  Hernández Fernandez de Rojas D, Ibanez E, Longhurst H, Maurer M, Fabien V, Aberer W, Bouillet L, Zanichelli A, Caballero T; IOS Study Group. International Archives Allergy Immunology 167, 21-28, 2015

• Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema.

  Aberer W, Maurer M, Reshef A, Longhurst H, Kivity S, Bygum A, Caballero T, Bloom B, Nair N, Albarn A. Allergy 69, 305-314, 2014

• Angioedema is not just “deep urticaria” but an entity of its own.

  Aberer W. Allergy 69, 549-552, 2014

• Classification, diagnosis, and approach to treatment for angioedema: con-sensus report from the Hereditary Angioedema International Working Group. 

  Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, Caballero T, Farkas H, Grumach A, Kaplan AP, Riedl MA, Triggiani M, Zanichelli A, Zuraw B
  Allergy 69, 602-616, 2014

• Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.

  Baş M, Greve J, Hoffmann TK, Reshef A, Aberer W, Maurer M, Kivity S, Farkas H, Floccard B, Arcoleo F, Martin L, Sitkauskiene B, Bouillet L, Schmid-Grendelmeier P, Li H, Zanichelli A. Allergy 68, 1452-1459, 2013

• Seltene Angioödeme und Angioödem-Simulatoren.

  Kränke B, Aberer W. Allergologie 36, 128-137, 2013

• Editorial: Angioödem – subkutanes Äquivalent der Urtikaria oder eigenständiges Krankheitsbild?

  Aberer W Allergologie 36, 83-84, 2013

• Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment.

  Maurer M, Aberer W, Bouillet L, Caballero T, Fabien V, Kanny G, Kaplan A, Longhurst H, Zanichelli A; IOS Investigators. PLoS One. 2013;8(2):e53773. doi: 10.1371/journal.pone.0053773. Epub 2013 Feb

• International Consensus on hereditary and acquired angioedema.

  Lang DM, Aberer W, Bernstein JA, Chng JJ, Sevciovic Grumach A, Hide M, Maurer M, Weber R, Zuraw B. Annals of Allergy Asthma Immunology 109, 395-402, 2012

• Hereditary angioedema treatment options: the availability of new therapies.

  Aberer W. Annals Medicine 44, 523-529, 2012

• Hereditary angioedema (HAE) in children and adolescents – a consensus on therapeutic strategies. 

  Wahn U, Aberer W, Eberl W, Faßhauer M, Kühne T, Kurnik K, Magerl M, Meyer-Olson D, Martinez-Saguer I, Späth P, Staubach-Renz P, Kreuz W:
  European Journal of Pediatrics 171, 1339-1348, 2012
  Monatsschrift Kinderheilkunde 160: 774-781, 2012

• Successful allogeneic cord blood transplantation in a patient with Evans syndrome leads to correction of hereditary angioedema type I as secondary effect. 

  Klausegger A, Wiednig M, Urban C, Lackner H, Reiter H, Bauer JW, Aberer W. Bone Marrow Transplantation 47, 1259-1261, 2012

• Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.

  Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, Toubi E, Werner S, Anné S, Björkander J, Bouillet L, Cillari E, Hurewitz D, Jacobson KW, Katelaris CH, Maurer M, Merk H, Bernstein JA, Feighery C, Floccard B, Gleich G, Hébert J, Kaatz M, Keith P, Kirkpatrick CH, Langton D, Martin L, Pichler C, Resnick D, Wombolt D, Fernández Romero DS, Zanichelli A, Arcoleo F, Knolle J, Kravec I, Dong L, Zimmermann J, Rosen K, Fan WT. New England Journal of Medicine 363, 532-541, 2010

• Haploinsufficiency due to deletion within the 3´-UTR of C1 INH-gene associated with hereditary angioedema.

  Laimer M, Klausegger A, Aberer W, Oender K, Steinhuber M, Lanschuetzer CM, Wally V, Hintner H, Bauer JW. Genetics in Medicine 8, 249-254, 2006

• Hereditary angioedema and normal C1-inhibitor activity in women.

  Kränke B, Salmhofer W, Aberer W. Lancet 356, 1440-1441, 2000